July 23, 2018 09:00 AM EDT
Financing

Fa­heem Has­nain ups cash haul to $330M for a fledg­ling biotech that is mov­ing ‘at light speed’

John Carroll

Editor & Founder

Just six months ago, Fa­heem Has­nain rolled out his lat­est biotech ven­ture with a $100 mil­lion mega-round for seed mon­ey. To­day, he’s adding $230 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

A service from the Financial Times